Should I buy or sell Aptevo Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" APVO shares. View APVO analyst ratings or view top-rated stocks .

How have APVO shares performed in 2024?

Aptevo Therapeutics' stock was trading at $7.9640 at the start of the year. Since then, APVO stock has decreased by 90.2% and is now trading at $0.7830. View the best growth stocks for 2024 here .

Are investors shorting Aptevo Therapeutics?

Aptevo Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 34,300 shares, an increase of 18.7% from the March 15th total of 28,900 shares. Based on an average daily volume of 122,800 shares, the days-to-cover ratio is currently 0.3 days. Currently, 5.1% of the company's shares are sold short. View Aptevo Therapeutics' Short Interest .

When is Aptevo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our APVO earnings forecast .

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) announced its quarterly earnings data on Tuesday, November, 14th. The biotechnology company reported ($22.00) EPS for the quarter, beating the consensus estimate of ($28.16) by $6.16.

When did Aptevo Therapeutics' stock split?

Aptevo Therapeutics's stock reverse split on Wednesday, March 6th 2024. The 1-44 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, March 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD) , Amarin (AMRN) , AVEO Pharmaceuticals (AVEO) , Alibaba Group (BABA) , Micron Technology (MU) , OPKO Health (OPK) , AbbVie (ABBV) , Aurinia Pharmaceuticals (AUPH) , BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO) .

How do I buy shares of Aptevo Therapeutics?

Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:APVO

Aptevo Therapeutics (APVO) Stock Price, News & Analysis

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)

Free APVO Stock Alerts

$0.78

-0.06 (-7.12%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.76
▼
$0.85
50-Day Range: $0.78
▼
$7.48
52-Week Range: $0.76
▼
$91.96

Volume: 465,918 shs
Average Volume: 204,535 shs
Market Capitalization: $336,690.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Aptevo Therapeutics alerts:

Aptevo Therapeutics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
5.13% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.06
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($57.83) to ($55.65) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.21 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Aptevo Therapeutics.

2.0

Short Interest

Percentage of Shares Shorted
5.13% of the float of Aptevo Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Aptevo Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aptevo Therapeutics has recently increased by 18.69%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Aptevo Therapeutics does not currently pay a dividend.
Dividend Growth
Aptevo Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for APVO.

2.3

News and Social Media Coverage

News Sentiment
Aptevo Therapeutics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Aptevo Therapeutics this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for APVO on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
MarketBeat Follows
3 people have added Aptevo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.90% of the stock of Aptevo Therapeutics is held by insiders.
Percentage Held by Institutions
Only 8.06% of the stock of Aptevo Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Aptevo Therapeutics are expected to grow in the coming year, from ($57.83) to ($55.65) per share.
Price to Book Value per Share Ratio
Aptevo Therapeutics has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

About Aptevo Therapeutics Stock (NASDAQ:APVO)

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

APVO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

APVO Stock News Headlines

April 14, 2024 | americanbankingnews.com

Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Increase in Short Interest

April 11, 2024 | msn.com

Why Aptevo Therapeutics Stock Is Cratering

April 16, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

April 11, 2024 | investorplace.com

Why Is Aptevo Therapeutics (APVO) Stock Down 56% Today?

April 10, 2024 | americanbankingnews.com

Aptevo Therapeutics (NASDAQ:APVO) Receives New Coverage from Analysts at StockNews.com

March 7, 2024 | marketwatch.com

Aptevo Therapeutics Up 20% on Positive Interim Data for Tumor Drug

March 7, 2024 | finance.yahoo.com

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

March 6, 2024 | ca.finance.yahoo.com

Aptevo Therapeutics Inc (AP8N.BE)

April 16, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

March 6, 2024 | investing.com

Aptevo Therapeutics enacts reverse stock split to meet Nasdaq requirements

March 5, 2024 | investorplace.com

APVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q4 2023

March 5, 2024 | finance.yahoo.com

Aptevo Therapeutics Inc (AP8N.DU)

March 4, 2024 | msn.com

Aptevo Therapeutics down 13%, will effect 1-for-44 reverse stock split

March 1, 2024 | uk.finance.yahoo.com

PD-1 and PD-L1 Inhibitors Competitive Landscape Report 2024: Clinical Assessment of Over 200 Drugs Being Developed by More than 180 Companies

February 9, 2024 | investing.com

Aptevo Therapeutics Inc (APVO)

February 7, 2024 | msn.com

Aptevo Therapeutics Stockholders Approve Reverse Split

January 24, 2024 | finance.yahoo.com

Aptevo Therapeutics Inc. (APVO)

November 22, 2023 | msn.com

Aptevo Therapeutics files to sell up to 32.03M shares of common stock for holders

November 14, 2023 | msn.com

Aptevo Therapeutics GAAP EPS of -$0.50

November 14, 2023 | finance.yahoo.com

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

November 1, 2023 | finanznachrichten.de

Aptevo Therapeutics: Aptevo to Present at Bio-Europe Conference

November 1, 2023 | finance.yahoo.com

Aptevo to Present at Bio-Europe Conference

October 21, 2023 | thestreet.com

With New Cash Aptevo Goes It Alone on Prostate Drug, Shares Up - Biotech Movers

September 26, 2023 | money.usnews.com

Aptevo Therapeutics Inc

August 10, 2023 | finance.yahoo.com

Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update

August 4, 2023 | finance.yahoo.com

Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering

August 3, 2023 | msn.com

Aptevo Therapeutics (APVO) Price Target Increased by 24.14% to 18.36

See More Headlines

Receive APVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 4/15/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:APVO
CUSIP: N/A
CIK: 1671584
Web: www.aptevotherapeutics.com
Phone: (206) 838-0500
Fax: 206-838-0503
Employees: 40
Year Founded: 2016

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,410,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -112.27%
Return on Assets: -64.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.64
Quick Ratio: 2.64

Sales & Book Value

Annual Sales: $3.11 million
Price / Sales: 0.11
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $28.58 per share
Price / Book: 0.03

Miscellaneous

Outstanding Shares: 430,000
Free Float: 420,000
Market Cap: $336,690.00
Optionable: Not Optionable
Beta: 4.89

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Marvin L. White (Age 62)
President, CEO & Director
Comp: $841.39k
Mr. Jeffrey G. Lamothe CA (Age 58)
Executive VP & COO
Comp: $722.51k
Ms. SoYoung Kwon J.D. (Age 55)
LL.M., Senior VP, General Counsel, Business Development & Corporate Affairs
Comp: $639.37k
Ms. Daphne L. Taylor (Age 58)
Senior VP & CFO
Dr. Dirk Huebner M.D. (Age 60)
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

Citadel Advisors LLC
Bought 262,124 shares on 2/15/2024
Ownership: 1.391%

View All Institutional Transactions

APVO Stock Analysis - Frequently Asked Questions

Should I buy or sell Aptevo Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" APVO shares.
View APVO analyst ratings or view top-rated stocks.
How have APVO shares performed in 2024?: Aptevo Therapeutics' stock was trading at $7.9640 at the start of the year. Since then, APVO stock has decreased by 90.2% and is now trading at $0.7830.
View the best growth stocks for 2024 here.
Are investors shorting Aptevo Therapeutics?: Aptevo Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 34,300 shares, an increase of 18.7% from the March 15th total of 28,900 shares. Based on an average daily volume of 122,800 shares, the days-to-cover ratio is currently 0.3 days. Currently, 5.1% of the company's shares are sold short.
View Aptevo Therapeutics' Short Interest.
When is Aptevo Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our APVO earnings forecast.

How were Aptevo Therapeutics' earnings last quarter?: Aptevo Therapeutics Inc. (NASDAQ:APVO) announced its quarterly earnings data on Tuesday, November, 14th. The biotechnology company reported ($22.00) EPS for the quarter, beating the consensus estimate of ($28.16) by $6.16.
When did Aptevo Therapeutics' stock split?: Aptevo Therapeutics's stock reverse split on Wednesday, March 6th 2024. The 1-44 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, March 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.
What other stocks do shareholders of Aptevo Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).
How do I buy shares of Aptevo Therapeutics?: Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APVO) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial